TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

TLSINYSE / NASDAQHealthcareSmall cap

$2.32+$0.14 (+6.7%)

Last close · Data as of Nov 20, 2026

Market cap
$202.7M
P/E
-5.2x
EV / EBITDA
-6.6x
Revenue
$45.2M
Net margin
-86.9%
ROCE
-113.1%

-53.2% over the last year

TriSalus Life Sciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-36.6%
3M
-55.6%
6M
-28.4%
1Y
-53.2%
5Y
-76.7%

52-week range

Day change +$0.14 (+6.7%) from $2.17 to $2.32 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TLSI, bought on each weekday since 2021.

News & filings

What TriSalus Life Sciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Current assets are 2.80 times current liabilities.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.

Read moreShow less

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Sector
Healthcare
Shares outstanding
50.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$202.7M
P/E
-5.2x
P/B
-6.0x
EV / EBITDA
-6.6x
EV / Sales
4.8x
P/S
4.5x
52-week high
$7.50
52-week low
$2.17

Profitability

Operating margin
-59.7%
Net margin
-86.9%
EBITDA margin
-73.2%
ROE
115.8%
ROCE
-113.1%
ROA
-111.0%
Asset turnover
1.28

Growth

Revenue
$45.2M
Revenue growth, 1Y
53.4%
Revenue CAGR, 3Y
53.9%
Net profit growth, 1Y
30.6%
Free cash flow
-$18.9M

Solvency

Current ratio
2.80
Debt / Equity
-1.02
Debt / Assets
0.97
CFO / Net profit
0.46
Cash / Market cap
10.1%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$45.1M
Cost of revenue$7.0M
Gross profit$38.2M
Operating expenses$65.1M
Research and development$15.0M
Selling, general and administrative$50.2M
Operating income-$26.9M
Interest and other-$12.3M
Pretax income-$39.2M
Tax and other$10.0k
Net income-$39.2M

Revenue and net profit

Revenue grew 53.4% in FY2025; net profit is the dashed line.

TriSalus Life Sciences, Inc. revenue and net profit by fiscal year
TriSalus Life Sciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$12.4M-$47.2M
FY2023$18.5M-$59.4M
FY2024$29.4M-$30.0M
FY2025$45.2M-$39.2M

Cash flows

FY2025: -$18.0M from operations, -$18.9M free after investment (dashed).

TriSalus Life Sciences, Inc. operating and free cash flow by fiscal year
TriSalus Life Sciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$32.3M-$33.1M
FY2023-$50.6M-$51.2M
FY2024-$40.8M-$41.2M
FY2025-$18.0M-$18.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$45.2M+53.4%1Y
EBITDA
-$33.0M
Net profit
-$39.2M
Cash from operations
-$18.0M
Free cash flow
-$18.9M
Revenue CAGR, 3Y
53.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$45.2M-$33.0M-$39.2M-$18.9M115.8%+53.4%+30.6%

Monthly returns

Month-by-month returns of TLSI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$35.3M
Liabilities$69.2M
Equity-$33.9M
Paid-in capital$296.7M
Retained earnings-$330.6M

Market cap against peers

8 peers: same sector, nearest by size.

  1. TriSalus Life Sciences, Inc. (this company)$202.7M

Peers map

Healthcare companies placed by value, growth and quality; TLSI highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. TriSalus Life Sciences, Inc. (this company)4.8x

Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
TriSalus Life Sciences, Inc.TLSIthis company$202.7M-5.2x-6.0x115.8%-6.6x
Atrium Therapeutics, Inc.RNA$210.4M-2.7x1.0x-37.0%0.7x
Accendra Health, Inc.ACH$202.9M-0.2x-0.4x238.8%9.3x
Sanara MedTech Inc.SMTI$202.7M-5.4x34.1x-632.5%22.7x
Embecta Corp.EMBC$202.3M2.1x-0.3x-14.6%4.9x
Alector, Inc.ALEC$201.0M—6.6x-466.3%—
Nkarta, Inc.NKTX$198.2M—0.6x-33.3%—
Anika Therapeutics, Inc.ANIK$196.8M-18.1x1.4x-7.6%-31.1x
Lucid Diagnostics Inc.LUCD$194.6M—17.8x-645.1%—
Peer median—-2.7x1.2x-35.2%4.9x

Year-to-date ROI

TLSI since 1 January, against earlier years.

Historical volatility

TLSI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

TriSalus Life Sciences, Inc. operating margin by fiscal year
TriSalus Life Sciences, Inc. operating margin by fiscal year
DateOperating margin
FY2022-293.9%
FY2023-294.3%
FY2024-122.9%
FY2025-59.7%
LineFY2025
Cost of revenueCost Of Revenue$7.0M
Gross profitGross Profit$38.2M
Operating expensesOperating Expense$65.1M
Research and developmentResearch And Development$15.0M
Total expensesTotal Expenses$72.1M
Pretax incomePretax Income-$39.2M

Learn while you research

Academy chapters picked for TriSalus Life Sciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing53% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →